Sign up for free insights newsletter
GR

Grifols S.A.

GRFBolsa de Madrid

Need professional-grade analysis? Visit stockanalysis.com

€8.84
+0.94%
End of day
Market Cap

$6.87B

P/E Ratio

19.87

Employees

25,258

Dividend Yield

N/A

Price Chart

Risk-Adjusted Performance

Ratio1W1M3M6M1Y5YScore
Sortino-2.50-2.18-2.15-0.17-0.47-1.23
Calmar-4.49-2.35-1.60-0.11-0.24-1.27
Sharpe-2.69-1.67-1.64-0.11-0.35-1.01
Omega0.230.660.701.010.980.80
Martin-8.28-6.10-3.46-0.27-0.34-2.72
Ulcer11.339.6114.1714.1249.9222.55

Grifols S.A. (GRF) Price Performance

Grifols S.A. (GRF) trades on Bolsa de Madrid in EUR. The company is classified in the Healthcare sector under the Drug Manufacturers - General industry. The stock currently trades at EUR8.84, up 0.94% from the previous close.

Over the past year, GRF has traded between a low of EUR7.32 and a high of EUR13.39. The stock has lost 0.0% over this period. It is currently 34.0% below its 52-week high.

Grifols S.A. has a market capitalization of $6.87B, with a price-to-earnings ratio of 19.87.

About Grifols S.A.

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Company Info

Exchange
Bolsa de Madrid
Currency
EUR
Country
Spain

Financial Metrics

Revenue (TTM)
$7.52B
EBITDA
$1.75B
Profit Margin
4.96%
EPS (TTM)
0.55
Book Value
7.61

Technical Indicators

52 Week High
€13.57
52 Week Low
€7.26
50 Day MA
€11.78
200 Day MA
€10.54
Beta
1.19

Valuation

Trailing P/E
19.87
Forward P/E
12.14
Price/Sales
0.84
Price/Book
1.21
Enterprise Value
$13.92B